Loading clinical trials...
Loading clinical trials...
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer
Conditions
Interventions
HyperAcute-Pancreas Immunotherapy
Gemcitabine
+1 more
Locations
75
United States
University of Alabama
Birmingham, Alabama, United States
University of South Alabama
Mobile, Alabama, United States
Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope National Medical Center
Duarte, California, United States
University of Southern California
Los Angeles, California, United States
Start Date
April 1, 2010
Primary Completion Date
May 1, 2016
Completion Date
May 1, 2016
Last Updated
May 28, 2020
NCT02600949
NCT03050268
NCT06423326
NCT07542041
NCT07283705
NCT07438106
Lead Sponsor
NewLink Genetics Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions